GHENT, BELGIUM--(Marketwire - August 21, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, will announce its half year results for 2008 on 28 August 2008.
